A Cost-Effectiveness Analysis of Glecaprevir/Pibrentasvir Versus Existing Direct-Acting Antivirals to Treat Chronic Hepatitis C in Japan.
Isao KawaguchiKazuaki ChayamaYuri Sanchez GonzalezSuchin VirabhakDominic MitchellCammy YuenHiromitsu KumadaPublished in: Advances in therapy (2019)
In GT1 treatment-naïve non-cirrhotic patients GLE/PIB was a cost-effective strategy compared to other DAAs. When a pan-genotypic framework was used, the GLE/PIB portfolio dominated the SOF-based portfolio.